Rockfish Bio AG

Rockfish Bio is a Vienna-based biotech company dedicated to promote healthy aging by developing senolytic therapies for the treatment of age-related diseases. We recently discovered a novel target pathway that is well-suited for the development of senolytic drugs with superior efficacy, selectivity and safety profile. Our target pathway was successfully tested in 7 different cell types with a therapeutic index of up to 700. Our lead candidate RFB01016 was able to restore neuromuscular functions and massively extend the health and life span (+40 % median survival time after start of treatment) in naturally aged mice. Proof-of-concept studies in several preclinical disease models are currently ongoing. This will demonstrate the efficacy of our approach for the treatment of age-related diseases and help us in the selection process for our first lead indication for IND-enabling studies.